Lantheus (NASDAQ:LNTH) Given “Market Outperform” Rating at JMP Securities

JMP Securities reiterated their market outperform rating on shares of Lantheus (NASDAQ:LNTH) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $112.00 target price on the medical equipment provider’s stock.

LNTH has been the subject of a number of other research reports. Truist Financial restated a “buy” rating and issued a $120.00 target price (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Finally, The Goldman Sachs Group started coverage on shares of Lantheus in a research report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 target price on the stock. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, Lantheus currently has a consensus rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Price Performance

LNTH stock opened at $91.58 on Tuesday. Lantheus has a 1 year low of $50.20 and a 1 year high of $126.89. The firm has a 50-day moving average of $89.64 and a 200 day moving average of $99.77. The company has a market cap of $6.37 billion, a P/E ratio of 15.24 and a beta of 0.46.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. UMB Bank n.a. lifted its stake in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock valued at $50,000 after acquiring an additional 134 shares during the period. Shelton Wealth Management LLC raised its holdings in shares of Lantheus by 77.8% during the fourth quarter. Shelton Wealth Management LLC now owns 11,969 shares of the medical equipment provider’s stock valued at $1,071,000 after purchasing an additional 5,237 shares during the last quarter. Procyon Advisors LLC lifted its position in Lantheus by 11.1% during the fourth quarter. Procyon Advisors LLC now owns 3,613 shares of the medical equipment provider’s stock valued at $323,000 after purchasing an additional 361 shares during the period. Empirical Asset Management LLC purchased a new stake in Lantheus in the fourth quarter worth approximately $323,000. Finally, Park Avenue Securities LLC grew its position in Lantheus by 26.4% in the 4th quarter. Park Avenue Securities LLC now owns 2,458 shares of the medical equipment provider’s stock worth $220,000 after purchasing an additional 513 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.